ReviewDiscover oncology2026
The potential of cytokine polymorphisms as biomarkers for oral squamous cell carcinoma: a systematic review.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
OSCC is a prevalent malignancy with devastating morbidity and mortality, increasing the need for innovative diagnostic strategies. Early and accurate prognosis remains a challenge. Polymorphisms in cytokines, crucial in immune regulation and cancer progression, may influence an individual’s susceptibility to OSCC and aggression. This review investigates the association between cytokine gene polymorphisms and OSCC susceptibility and finding potential biomarkers for OSCC. A comprehensive search of PubMed, Google Scholar and Scopus databases was conducted using relevant keywords. Studies evaluating the association between cytokine gene polymorphisms and OSCC risk, prognosis, and treatment were included. This review included 31 studies across 4 continents, primarily using a case-control design. Majority of the studies came from Asia (21 studies). Most participants were ≥ 45 years old and male. Common risk factors were tobacco use, alcohol consumption, and betel nut chewing. HPV16 infection was also linked to increased risk in some studies. Polymorphisms in TGF-β, IL-6, VEGF, IL-17 A, IL-17 F, IL-1α, IL-8, IL-16 and IL-18 genes were associated with elevated OSCC risk in various studies. Although they are protective, mutations IL-10-1082 A/G, IL-10-819 T/C and IL-10-592 A/C were linked to increased OSCC risk or pre-cancer lesions. While this systematic review highlights the potential of cytokine polymorphisms as biomarkers for OSCC, the evidence is inconclusive due to heterogeneity of findings. Ethnic and geographical differences need to be studied further for optimised personalised therapeutic options. Cytokine polymorphisms have potential as biomarkers for OSCC but have not been fully realised. There is need for further studies in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.